Press Releases

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June

— Researchers to Present New Phase 2 Data Showing Safety and Anti-Leukemic Activity with WU-CART-007 and Additional New Findings for this Investigational, Off-the-Shelf Allogeneic CAR-T Cell Therapy —

— Company to Initiate Follow-Up Study in Q4 2024 with WU-CART-007 in Pediatric and Minimal Residual Disease (MRD) Patients — 

— Will Share New Data for WU-NK-101, its Investigational Memory Natural Killer Cell Therapy, at EHA —

 ST. LOUIS, MO and SAN DIEGO, CA, May 20, 2024 – Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced receipt of two new regulatory designations for its investigational CAR-T cell therapy, WU-CART-007, that it anticipates will expedite regulatory reviews on two continents.

Specifically, Wugen received Regenerative Medicine Advanced Therapy (RMAT) designation in the United States and PRIME (“Priority Medicines”) designation in the European Union for WU-CART-007 for the treatment of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Both designations provide increased agency support to expedite the development and review of promising therapies for patients in need.  

Regulators granted Wugen these designations following their reviews of data including results from the global Phase 1/2 clinical trial for the treatment of R/R T-ALL/LBL. Additional information is available on, identifier NCT# 04984356. The newest data from the Phase 1/2 study will be presented by Ibrahim Aldoss, M.D., City of Hope, on June 14 during the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain.

“Our goal is to bring this investigational off-the-shelf allogeneic CAR-T treatment to patients as soon as possible,” said Kumar Srinivasan, Ph.D., M.B.A., Wugen president and chief executive officer. “These designations represent a significant opportunity to accelerate regulatory reviews for WU-CART-007 as we conclude Phase 1/2 trials and begin pivotal studies later this year.”

“The FDA and EMA granted these designations for WU-CART-007 based on the rigor of our data and the potential of WU-CART-007 in addressing serious unmet needs of patients suffering from resistant blood cancers following treatment with current therapies,” said Jan Davidson-Moncada, M.D., Ph.D., chief medical officer of Wugen.

About RMAT and PRIME Designations

The U.S. Food and Drug Administration’s Center for Biologic Research and Evaluation grants RMAT designation for regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition as well as having preliminary clinical evidence indicating their potential to address unmet medical needs for a serious condition. EMA’s PRIME scheme is designed for medicines that demonstrate the potential to address an unmet medical need.

WU-CART-007 previously received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration for the treatment of R/R T-ALL/LBL.

Wugen Presentations at EHA

These abstracts will be presented at the hybrid EHA 2024 meeting:

Oral Presentation

Title: WU-CART-007, an Allogeneic CAR-T Cell Targeting CD7, is Highly Effective Against Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL)  

Presenter: Ibrahim Aldoss, M.D., City of Hope, Duarte, CA

Abstract/Presentation ID: S110

Date/time: Friday, June 14, 14:45-15:00 CEST (8:45-9:00 a.m. U.S. ET) 

Poster Presentations

Title: Preliminary Effect of Enhanced Lymphodepletion (ELD) on WU-CART-007 in T-ALL/LBL

Presenters: Ouiam Bakkacha M.D. and Ben Capoccia Ph.D., Wugen, St. Louis, MO

Abstract: P408

Title: WU-NK-101 is an Off-The-Shelf memory NK Cell with a Time-Resilient, Anti-Tumor Phenotype that can be Detected in R/R AML Patient PBMC After Infusion

Presenter: Laura Arthur, Ph.D., Wugen, St. Louis, MO

Abstract: P1422

About WU-CART-007

WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. WU-CART-007 is currently being evaluated in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL). Additional information is available on, identifier NCT# 04984356. WU-CART-007 has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration for the treatment of R/R T-ALL/LBL.

About WU-NK-101

WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-induced memory-like (CIML) phenotype. This cell population has a superior phenotype, proliferation capacity, and metabolic fitness, making it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML). Wugen is planning to initiate solid tumor studies of WU-NK-101 in combination with cetuximab. Studies of WU-NK-101 to date have shown promising robust in vivo activity in various tumor indications, retention of anti-cancer activity in TME, resistance to immune suppression, and enhanced activity with checkpoint inhibitors. WU-NK-101 has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML. 


About Wugen

Wugen, Inc. is a clinical-stage biotechnology company developing the next generation of off-the-shelf CAR-T and memory natural killer (NK) cell therapies for cancer. For more information, please visit

Investor Contact:

Mark Lewis



Media Contact:

Christine Fanelle

Scient PR